Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101. Open-label, multicentre, phase I/II. [Behandlung von fortgeschrittenen Tumoren des Gastrointestinal-Traktes in einer Phase I/II Studie mit modifizierten autologen MSC_apceth_101. Offen, multizentrische Phase I/II.]

Trial Profile

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101. Open-label, multicentre, phase I/II. [Behandlung von fortgeschrittenen Tumoren des Gastrointestinal-Traktes in einer Phase I/II Studie mit modifizierten autologen MSC_apceth_101. Offen, multizentrische Phase I/II.]

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Agenmestencel-T (Primary) ; Ganciclovir
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TREAT-ME 1
  • Sponsors Apceth
  • Most Recent Events

    • 23 Mar 2017 Status changed from recruiting to discontinued.
    • 07 Oct 2016 This trial was completed in Germany, according to Eudra record.
    • 02 Jun 2015 Tolerability results (phase 1) presented at the 51st Annual Meeting of the American Society of Clinical Oncology. No safety concerns to prevent progression to phase II testing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top